Metformin provides superior neuroprotective potential compared to semaglutide in preventing diabetes-associated Alzheimer’s disease via dual actions

These findings reveal that diabetes therapies differ in their ability to protect against AD. Metformin shows the strongest potential, supporting its prioritization for targeted studies in people with diabetes who are at high risk of AD, and highlighting the importance of precision medicine in future prevention trials.